DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines
$599,925N43FY2023AINIH
Molecular Express, Inc., Rancho Dominguez CA
Investigators
Abstract
The contractor will generate analogues of signal modifiers and co-formulate them with monophosphoryl lipid A using the contractorâs proprietary VesiVax liposomal system.
View original record on NIH RePORTER →